EZH2 and Miyoshi myopathy: In summary, our data reveal a molecular mechanism whereby KDM6A mediates ADCC not only through regulating CD38 but also by modulating NK activity through CD48 regulation, demonstrating the therapeutic potential of EZH2 inhibitor in MM treatment to overcome Dara resistance and providing the preclinical rationale for a Dara-based combination therapeutic strategy to improve patient outcome in MM (Fig. 8).